Rilzabrutinib

Sanofi presents 39 abstracts at EADV 2024, highlighting Dupixent's impact on IL4/IL13 in AD, PN, CSU, and clinical remission in children with AD. Data also showcase pipeline molecules like amlitelimab and rilzabrutinib in AD and CSU.

Rilzabrutinib's LUNA 3 phase 3 study met its primary endpoint, showing significant durable platelet response in ITP patients. Regulatory submissions in the US and EU are expected by year-end. Rilzabrutinib, part of Sanofi's immunology pipeline, is also being studied for other immune-mediated diseases.

IgG4-RD is a fibroinflammatory disease affecting multiple organs, with B and T cells playing key roles in its pathogenesis. Diagnosis requires clinicopathological correlation due to the lack of specific tests. Glucocorticoids are effective but limited by toxicity, prompting research into glucocorticoid-sparing agents. B cell-targeted therapies like rituximab show promise, though more randomized trials are needed. Untreated IgG4-RD can lead to irreversible organ damage, emphasizing the need for close monitoring and long-term immunosuppression in some cases.